person · Reporting owner
Tomlin Stephen Lawrence
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ANAPTYSBIO, INC
Report date July 26, 2017 · Filed July 28, 2017
Jointly reported with Avalon Ventures VII L P, AVALON VENTURES VII GP, LLC, Kinsella Kevin J
Section 16 reporting ended · disclosed 2017-07-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,636,945 |
Reported balance
After 2017-07-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-07-26 · Other · Disposed 399,987 · Balance 1,636,945 F1: Represents a pro-rata in-kind distribution of Common Stock by Avalon Ventures VII, L.P. effected on July 26, 2017 without consideration to its limited partners and to its general partner, Avalon Ventures VII GP, LLC. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 37,040 |
Reported balance
After 2017-07-26 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-07-26 · Other · Acquired 37,040 · Balance 37,040 F2: Represents the receipt by Avalon Ventures VII GP, LLC, the general partner of Avalon Ventures VII, L.P., of its pro-rata portion of the in-kind distribution described in footnote 1. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2017-07-26 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2017-07-26 · Sale · Disposed 37,040 · Balance 0 F3: Represents the open-market sale by Avalon Ventures VII GP, LLC, the general partner of Avalon Ventures VII, L.P., of the Common Stock received as a result of the in-kind distribution described in footnote 1. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of Common Stock by Avalon Ventures VII, L.P. effected on July 26, 2017 without consideration to its limited partners and to its general partner, Avalon Ventures VII GP, LLC.
F2: Represents the receipt by Avalon Ventures VII GP, LLC, the general partner of Avalon Ventures VII, L.P., of its pro-rata portion of the in-kind distribution described in footnote 1.
F3: Represents the open-market sale by Avalon Ventures VII GP, LLC, the general partner of Avalon Ventures VII, L.P., of the Common Stock received as a result of the in-kind distribution described in footnote 1.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2017 Filed Jul 28, 2017 15:52 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 37,040 | $24.35 | $901,924.00 |
DisclosureSEC source: 0000899243-17-019280 · doc4.xml · nonDerivative · entry 3 Avalon Ventures VII L P · CIK 0001318999 · 10% owner AVALON VENTURES VII GP, LLC · CIK 0001380392 · 10% owner · See Remarks Kinsella Kevin J · CIK 0001311643 · 10% owner · See Remarks Tomlin Stephen Lawrence · CIK 0001695652 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Represents the open-market sale by Avalon Ventures VII GP, LLC, the general partner of Avalon Ventures VII, L.P., of the Common Stock received as a result of the in-kind distribution described in footnote 1. F3 · ownership.nature: Represents the open-market sale by Avalon Ventures VII GP, LLC, the general partner of Avalon Ventures VII, L.P., of the Common Stock received as a result of the in-kind distribution described in footnote 1. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 15:52 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | OtherCommon Stock | 37,040 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019280 · doc4.xml · nonDerivative · entry 2 Avalon Ventures VII L P · CIK 0001318999 · 10% owner AVALON VENTURES VII GP, LLC · CIK 0001380392 · 10% owner · See Remarks Kinsella Kevin J · CIK 0001311643 · 10% owner · See Remarks Tomlin Stephen Lawrence · CIK 0001695652 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 37,040 F2 · kind: Represents the receipt by Avalon Ventures VII GP, LLC, the general partner of Avalon Ventures VII, L.P., of its pro-rata portion of the in-kind distribution described in footnote 1. F2 · ownership.nature: Represents the receipt by Avalon Ventures VII GP, LLC, the general partner of Avalon Ventures VII, L.P., of its pro-rata portion of the in-kind distribution described in footnote 1. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 15:52 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | OtherCommon Stock | 399,987 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019280 · doc4.xml · nonDerivative · entry 1 Avalon Ventures VII L P · CIK 0001318999 · 10% owner AVALON VENTURES VII GP, LLC · CIK 0001380392 · 10% owner · See Remarks Kinsella Kevin J · CIK 0001311643 · 10% owner · See Remarks Tomlin Stephen Lawrence · CIK 0001695652 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,636,945 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock by Avalon Ventures VII, L.P. effected on July 26, 2017 without consideration to its limited partners and to its general partner, Avalon Ventures VII GP, LLC. F1 · ownership.nature: Represents a pro-rata in-kind distribution of Common Stock by Avalon Ventures VII, L.P. effected on July 26, 2017 without consideration to its limited partners and to its general partner, Avalon Ventures VII GP, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.